ImmVirX

Receptor Targeted Oncolytic Viruses

Corporate Presentation

February 2024

Disclaimer

This presentation comprises general information only. This presentation shall not be construed as a prospectus or an offer to sell or issue, or a solicitation of an offer to buy, any security in any jurisdiction.
THIS PRESENTATION MAY NOT BE COPIED OR REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE, IN PARTICULAR THIS PRESENTATION AND ITS CONTENTS ARE STRICTLY CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND DEPENDENCIES, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

Disclaimer

This presentation has been prepared by ImmVirx Pty Ltd (ACN 634 890 761) (**ImmVirX**) to provide summary information about ImmVirX and certain plans and objectives of ImmVirX. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes and should not be relied upon by any person. No representation or warranty, express or implied, is made by any person as to the fairness, accuracy, completeness or correctness of the information contained in this presentation. This presentation does not purport to summarise all information that a person should consider when making any decision to enter into any transaction with ImmVirX or any other party, and should not form the basis of any decision by a person.

Reliance should not be placed on the information or opinions contained in this presentation, and it is subject to change. This presentation is for informational purposes only and is not financial product or investment advice, or a recommendation or invitation to enter into any transaction with ImmVirX or any other party, or a representation that ImmVirX or any other party will be entering into any transaction. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular person. Each recipient should conduct their own investigations of any transaction with ImmVirX or any other applicable party, as well as analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of ImmVirX and its business, and the contents of this presentation. Recipients should seek their own legal, financial, tax and other professional advice in connection with any transaction with ImmVirX or any other party.

ImmVirX assumes no liability

To the maximum extent permitted by law, none of ImmVirX nor any of its subsidiaries, affiliates and related bodies corporate, nor any of their respective officers, directors, employees, advisers and agents (**Related Parties**), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning the content of this presentation, ImmVirX or any securities or any transaction that ImmVirX or other applicable party may enter into including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of, or reliance on, any of the information contained in this presentation or otherwise arising in connection with it. To the maximum extent permitted by law, ImmVirX, each of its subsidiaries and each of their Related Parties disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

This presentation is strictly confidential

This presentation is confidential and not for further distribution. It is provided on the basis that, by accepting this presentation, persons to whom this presentation is given agree to keep the information confidential, not copy the presentation and not to disclose it, in whole or in part, to anyone except to their professional advisers on a need-to-know basis and subject to the same confidentiality restrictions as set out above.

Past and future performance

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This presentation contains certain forward-looking statements, including with respect to the financial condition, operations and business of ImmVirX and certain plans and objectives of ImmVirX. Such forward looking statements involve known and unknown risks, uncertainties and other factors that because of their nature may cause the actual results, performance or actions of ImmVirX, or any other party, to be materially different from the results, performance or actions expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding ImmVirX's present and future business strategies and the political and economic environment in which ImmVirX will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts.

Reservation of rights

Neither of ImmVirX nor any other party has committed to entering into any transaction and, and to the extent permitted by law or regulatory code, it reserves all rights in relation to the conduct of any transaction, including without limitation: (1) the right to negotiate with one or more prospective parties at any time; (2) to enter into binding documentation in relation to any transaction; (3) provide or not to provide additional information and to provide differential information to different parties; (4) to withdraw from discussions; or (5) to vary (in whole or in part) or terminate any transaction, at any time without notice or reasons to any party.

Restrictions

The distribution of this presentation or any information contained in it, and the offering or sale of securities may be restricted by law in certain jurisdictions, and therefore any person into whose possession any document containing this presentation or any part of it comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions could result in a violation of the laws of such jurisdiction. Recipients of this presentation are required to inform themselves of, and comply with, all such restrictions or prohibitions and neither ImmVirX nor any other person accepts any liability to any person in relation thereto.

The securities of ImmVirX have not been and will not be registered under the US Securities Act of 1933, as amended (**US Securities Act**). There will be no public offering of the ImmVirX's securities in the United States. The securities will be offered and sold solely (a) in the United States to investors that are (i) a "qualified institutional buyer" (**QIB**) as defined in Rule 144A under the US Securities Act or (ii) a dealer or other professional fiduciary organized, incorporated or (if an individual) resident in the United States that is acting solely for a discretionary or similar account (other than an estate or trust) held for the benefit or account of a person that is not a U.S. Person (as such term is defined in Rule 902(k) under the US Securities Act) for which it has sole investment discretion (**Eligible U.S. Fund Manager**); or (b), outside the United States in "offshore transactions" in reliance on Regulation S. Any failure to comply with this restriction may constitute a violation of United States securities laws.

Agreement

By accepting receipt of or electronically accessing this presentation or attending any presentation or delivery of this presentation you agree to be bound by the foregoing limitations and conditions and, in particular, will be taken to have represented, warranted, undertaken and acknowledged to ImmVirX that: (i) you are able to receive this presentation without contravention of any applicable legal or regulatory restrictions; (ii) if you are in Australia, you are either a professional investor or sophisticated investor (as those terms are defined by section 708(8) and (11) of the *Corporations Act 2001* (Cth); (iii) you are not located in the United States and will not transmit or send any information contained in this presentation to any other persons in the United States or to any publications with a general circulation in the United States, or, if you are located in the United States, you are a QIB or an Eligible US Fund Manager; (iv) you will not rely on this presentation for the purposes of any involvement in any offering of ImmVirX's securities; and (v) you will not record, distribute, copy, reproduce, publish, store in a retrieval system, transmit or pass on this presentation, directly or indirectly, in whole or in part.

ImmVirX - Clinical Stage Oncology Company

AMBITION

To provide durable responses and high quality of life in patients with some of the most globally prevalent cancer types using our proprietary bio-selection platform to develop receptor targeted, RNA oncolytic picornaviruses

APPROACH

- Highly inflame “cold” tumor types with current low responsiveness to immune checkpoint therapy
- Trigger both innate and adaptive immune responses and infiltrate tumors with immune cells at a high rate
- Activate immune stimulating genes to create synergy with immune checkpoint and CAR-T therapies
- Favourable safety profile for patients - off the shelf therapy / no need for personalisation

PROGRESS

- Operations initiated in April 2020 following seed financing
- First patient dosed with lead asset, IVX037, in April 2023 – net cashburn of $A11m to that time
- Second asset, IVX055, bioselected and advancing to the clinic
- Partnered with Innovent Biologics for Phase 1b combination study

Experienced Team Driving ImmVirX into the Clinic

Dr. Malcolm McColl
CEO and Co-Founder

Prof. Darren Shafren
CSO and Co-Founder

Dr Jeannie Joughin
Non-Executive Director

Dr. Leonard Post
Non-Executive Director

Robert Routley
Non-Executive Director

Robert Vickery
Co. Sec & CFO

Cohesive Team with record of Success

- Leadership and scientific team comprised of ex-Viralytics team members responsible for invention, preclinical and clinical development of CAVATAK technology through to acquisition by Merck for $A502M
- Deep regulatory knowledge with extensive interactions with FDA
- GMP manufacturing and quality systems experience
- Global networks of clinicians and KOLs to facilitate clinical programs
- 27 strong R&D team in facility at University of Newcastle Hunter Medical Research Institute
- Strong balance sheet - $31.6M cash on February 9 2024
- **Partnered with Innovent Biologics for assessment of TYVYT® (sintilimab) and IVX037 in Phase 1b study**

Excellent Operations Team (ex Viralytics, Merck)

Strong Bench to Clinic capability

Dr. Min Quah

Director
Discovery & Pre-clinical Research

Bronwyn Davies

Director
CMC

Dr. Susanne Johansson

Director
Quality Management

Dr. Yvonne Wong

Director
Manufacturing Science

Dr. Jennifer Rosenthal

Director
Quality & Regulatory Affairs

Dr. Roberta Karpathy

Director
Clinical Science

Dr Naomi Croll

Consultant Project Manager
Clinical Operations

Proven Oncolytic Virus Development Team

- Preclinical development and translation of Viralytics' CAVATAK into clinic
- Established advanced preclinical models to assess immunotherapy combinations
- Manufacturing experience across AU/US/UK
- Managed multiple clinical trials across AU/US/UK sites ~ 300 CAVATAK patients
- Tech transfer to Merck from 2018-2019

MERCK

Viralytics
Developers of Oncolytic Immunotherapies

Oncolytic Viruses: Expanding the Reach and Impact of Immunotherapy

- Immunotherapies including checkpoint inhibitors have been transformative, but only for a subset of patients
- Despite limitations, the cancer immunotherapy market is projected to reach USD$277B by 2030*

Oncolytic virus immunotherapies are an emerging class of combination therapy agents with **big pharma interest** and the potential to **expand the reach** of immunotherapy to **indications not currently responsive** to checkpoint inhibitors

Validating high value oncolytic virus transactions and valuations

Amgen acquisition of Biovex

USD$425M cash upfront, USD$575M future milestone payments

Merck acquisition of Viralytics

A$502M cash upfront

CG Oncology IPO

Market cap ~ USD$3Bn (Feb 16 2024) following $380m IPO

ImmVirX

* Precedence Research Dec 2021

ImmVirX Targeting Substantial Markets

Estimated number of deaths worldwide, both sexes, all ages



ImmVirX

International Agency for Research on Cancer
World Health Organization

High Unmet Need with Current Treatments

Indication	Forecast Deaths per Annum 2022		Clinical Response	
	USA[1]	China[1]	ICI ORR[3]	Study Identifier
Colorectal[2]	**56,693**	**309,114**	**4% KEYTRUDA**	**KEYNOTE-028**
Ovarian	**14,914**	**39,306**	**9% KEYTRUDA**	**KEYNOTE-100**
Gastric	**11,898**	**400,415**	**17% KEYTRUDA**	**KEYNOTE-224**
Hepatocellular	**32,332**	**412,216**	**16% KEYTRUDA**	**KEYNOTE-224 (cohort 2)**
Lung Cancer[4]	**144,913**	**766,898**	**18% KEYTRUDA**	**KEYNOTE-010**
Melanoma (CAVATAK™ lead target indication)	7,530	4,369	33% KEYTRUDA	KEYNOTE-006

[1] Chinese Medical Journal 2022; 135(5)
[2] Includes all types of colorectal cancer (CRC). ImmVirX focus on MMRp (Mismatch Repair Proficient) accounting for ~94% of all CRC (Dung et al., Science, 2017; 357 (6349):409-413).
[3] ICI ORR = Immune Checkpoint Inhibitor Overall Response Rate
[4] Non small cell lung cancer with tumor proportion score >1%

Limited Efficacy and Significant Toxicity of Therapies in Colorectal Cancer

- TAS-102 is an oral chemotherapy used in late-stage CRC
- Large randomized trial demonstrated that TAS-102 improved median overall survival by 1.8 months
- TAS-102 associated with significant adverse events including neutropenia and leukopenia
- Urgent need for better therapies in this setting to extend survival without significant toxicity



Mayer RJ et al. *N Engl J Med* 2015; 372:1909-1919

ImmVirX: Receptor Targeted Oncolytic Virus

Platform

- Proprietary bio-selection platform for receptor targeted oncolytic RNA viruses
  - IVX037 in phase 1
  - IVX055 in preclinical development
- Selection for extracellular receptor targeting drives exquisite selectivity and potency in specific tumor types
- Oncolytic potency enables development of non-genetically modified virus with potential for future “armed” virus to express key immune stimulatory molecules

Proven Mechanism

- RNA virus drives tumor inflammation and immune cell infiltration via RIG-I pathway activation
- De-risked through preclinical in vitro and *in vivo* proof-of-concept.
- Comparable to oncolytic activity and molecular mechanism of CAVATAK but now in other tumor types and using different receptor.

Clinical Strategy

- Virus specificity of IVX037 enables targeted approach in indications with high unmet needs including colorectal, gastric, ovarian and liver cancer
- Planned combination therapy with immune checkpoint inhibitors in indications with poor response rates
- Clinical program advancing – Recruitment in cohort 1 and 2 complete. Cohort 3 near completion
- No dose limiting toxicities in first two cohorts. Several sites recruiting.

Pre-Clinical Data: IVX037

Lead Candidate
Receptor Targeted
RNA Oncolytic Virus

Measuring *In Vivo* Oncolytic Activity of IVX037

Human cancer xenograft model

Day 0

Implant human cancer* cells into left flank



SCID Balb/C

Single intratumoral treatment with IVX037 or control



IVX037
or control i.t

End of study

Monitor for tumor burden and treatment tolerance



Monitor

* Assessing human colorectal (X2), gastric (X1) and ovarian (X2) cancer cell lines in initial studies

IVX037: *In Vivo* Oncolytic Activity in Colorectal Cancer

Two human MSS colorectal cancer cell lines assessed in xenograft models

Colorectal tumor model #1 – **WiDr**



Colorectal tumor model #2 – **Caco-2**



Striking impact in two colorectal cancer models in immune deficient mice provides clear signal of potency solely attributed to oncolytic activity of IVX037 with favorable tolerability

IVX037: *In Vivo* Oncolytic Activity in Ovarian Cancer

Two human ovarian cancer cell lines assessed in xenograft models

Ovarian tumor model #1 – **IGROV-1**



Ovarian tumor model #2 – **OVSAHO**



Striking reduction in tumor volume provides clear signal of potency solely attributed to oncolytic activity of single dose of IVX037 with favorable tolerability

IVX037: Demonstrated *In Vivo* Oncolytic Activity in Gastric Cancer

Human Gastric cancer (NCI-N87) xenograft model



Activity of single dose of IVX037 demonstrated in gastric cancer with favorable tolerability

Potency Observed Across Dose Levels

Dose escalation in human MSS colorectal cancer (WiDr) xenograft model



IVX037 potency enables robust antitumor activity at a 10,000-fold lower dose

Measuring *In Vivo* Oncolytic Activity of IVX037 Intravenously

Human MSS colorectal cancer (WiDr) xenograft model – intravenous delivery



Intravenous Delivery of IVX037 Achievable in Colorectal Xenograft

Human MSS colorectal cancer (WiDr) xenograft model – intravenous delivery







Evidence of impressive anti-tumor efficacy and no treatment related toxicity observed

In the Clinic

Lead Candidate IVX037
Receptor Targeted
RNA Oncolytic Virus

Clear Path Forward in the Clinic



Clinical strategy leverages potential to:

- De-risk program with early biomarker data
- Develop biomarker informed/stratified future programs

IT – intratumoral IV - intravenous
MSS-CRC – Microsatellite Stable Colorectal Cancer
RP2D – Recommended Phase 2 Dose

Escalating viral dose and volume during cohort advancement in Phase 1a



*, Up to 7 doses permitted at Investigator discretion in absence of DLTs'

IVX037 well tolerated and immunogenic in seronegative patients



Evidence of secondary viral replication

- with persistence of virus in patient serum



Significant elevation of CXCL10 following administration of IVX037

- favorable biomarker activation for success in combination with CPI*



Serum level of CXCL10

*Silk AW et al. Cancer Immunol Immunother. 2023 Jun;72(6):1405-1415

Early Positive Signals in the Clinic

- commencing greater dose number / volume

- IVX037 dosing in Cohorts 1 and 2 is complete, with near completion of Cohort 3
- To date IVX037 intralesional administration has been well tolerated, with all patients exhibiting some level of systemic exposure immediately following injection with no dose-limiting toxicities observed
- Mild flu-like reactions after injection (fatigue, chills, rigors) and injection site discomfort observed
- IVX037 has been successfully administered to liver, lymph node and abdominal metastases
- Preliminary serum biomarker analysis has indicated early signs of IVX037 induction of beneficial inflammatory cytokines/chemokines, such as CXCL10
- Recruitment is ongoing and Phase 1b in combination with CPI, sintilimab to commence in mid-2024

Recent Milestones

Preclinical / IP / Corporate

- In-vitro liver cancer cell line studies complete with demonstrated activity in this setting
- Bioselection complete of second asset, IVX055, to target lung cancer
- Executed Clinical Trial Collaboration and Supply Agreement with Innovent as partner in Phase 1b study assessing IVX037 and TYVYT® (sintilimab)
- Patent filed including Composition of Matter claim
- RDTI - $3.8M payment to ImmVirX

CMC / Quality

- Successful completion of first GMP batch at US CDMO site
- Second GMP batch underway at US CDMO site
- Enhanced formulation of IVX037 Drug Product stable for 20 weeks at 2-8ºC with study ongoing

Clinical

- Four sites open for recruitment - strong clinician engagement
- Cohorts 1 and 2 are complete with Cohort 3 dosing near completion
- IVX037 intralesional administration has been well tolerated with no dose-limiting toxicities observed
- IVX037 has been successfully administered to liver, lymph node and abdominal metastases
- Preliminary serum biomarker analysis has indicated early signs of IVX037 induction of beneficial inflammatory cytokines/chemokines, such as CXCL10

Upcoming Milestones – through to mid 2024

Preclinical / IP

- Complete in vivo preclinical assessment of IVX037 in liver cancer indication
- Preclinical assessment of activity of IVX055 in lung cancer
- File provisional patent for IVX055

CMC / Quality

- Complete second GMP batch at US CDMO
- Further stability data on improved formulation
- Progress on enhancement of production process in collaboration with US CDMO
- Initiate production of IVX055 for clinical studies

Clinical

- Phase 1a advancing through dose expansion
- Open new sites as commence Phase 1b and new indications
- Phase 1b for colorectal cancer to be initiated with multidose IVX037 and TYVYT® (sintilimab)
- US FDA IND filing

Summary

- **Clinical stage oncology company with platform technology**
- Early positive signals with IVX037 in the clinic and well tolerated by patients
- Clinical trial collaboration with Innovent Biologics for Phase 1b study (with supply of sintilimab)
- Major opportunity in most important cancers with high unmet need
- Strong preclinical data set across multiple cancer types
- Successful manufacture of IVX037 at US CDMO site
- Ability to further partner / licence / sell / list as clinical data unfolds
- Bioselected second asset, IVX055, targeting NSCLC using our proprietary platform
- Strong cash position - $31.6M (9 Feb 2024) runway to early 2026

ImmVirX

Receptor Targeted Oncolytic Viruses

Thank You

Malcolm McColl
Chief Executive Officer and Co-Founder
malcolm.mccoll@immvirx.com